
What smart money is saying about Vimian Group AB
1 fund in our archive has pitched Vimian Group AB — most recently Protean in March 2026.
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Also mentioned · 1
These funds discuss Vimian Group AB — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedProtean Funds Partner LetterApril 2026
“We also benefited from strong quarterly reports from companies such as Vimian, Autoliv and AAK.”
Read the letterVimian Group AB
Fund coverage · 1 thesis
- ProteanMarch 2026
Vimian Group AB is a pet-focused animal health platform recovering operationally with improved cash flow and margins, trading at a discounted valuation with attractive thematic exposure.
Read the full thesis
Read every full thesis on Vimian Group AB
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→